Abstract: The present invention concerns new immunosuppressive and antiviral pharmaceutical agents using lipid alcohols of the general formulae I and II in which R1 represents a straight-chained or branched, saturated or unsaturated alkyl chain with 1-30 carbon atoms which can optionally be substituted once or several times by halogen, C1-C6 alkoxy, C1-C6 alkylmercapto, C1-C6 alkoxycarbonyl, carboxy, C1-C6 alkylsulfinyl or C1-C6 alkylsulfonyl groups, R2 represents hydrogen, a straight-chained or branched, saturated or unsaturated alkyl chain with 1-20 carbon atoms which can optionally be substituted once or several times by halogen, C1-C6 alkoxy, C1-C6 alkylmercapto, C1-C6 alkoxycarbonyl or C1-C6 alkylsulfonyl groups, X represents a valency dash, oxicarbonyl, carbonyloxy, amidocarbonyl, carbonylamido, oxygen, sulphur, a sulfinyl or sulfonyl group Y represents a valency dash, oxicarbonyl, carbonyloxy, amidocarbonyl, carbonylamido, oxygen, sulphur, a sulfinyl or sulfonyl group n represents an integ

Abstract: A method of replenishing plasmalogens in mammals comprising treatment with a plasmalogen-replenishing-effective amount of one or more stantially pure monoethers of glycerols and their carboxylic acid ester derivatives of Formula I: wherein R is a C12-C22 linear or branched alkyl or alkenyl group; and R1 and R2 are, each independently, hydrogen or an acyl moiety {—C(═O)—R3} wherein R3 is a linear or branched C1-C30 alkyl or alkenyl; and pharmaceutically-acceptable salts thereof, is disclosed. Nutritional supplements, dietary supplements and food additives comprising one or more substantially pure compounds of Formula I is also disclosed.

Abstract: Composition in the form of an aqueous solution, useful for disinfecting hard surfaces comprises: a) from 0.0005% to 20% by weight of peracetic acid, b) from 0.001% to 45% by weight of acetic acid, c) from 0.001% to 35% by weight of hydrogen peroxide, d) from 0.0001% to 2% by weight of at least one compound of formula (I) (R1) (R2) (R3)N→O  (I) e) if desired, up to 2.5% by weight of at least one nonionic surfactant, and wherein f) the weight ratio between the compound of formula (I) and the peracetic acid is less than or equal to 1, and in that g) the weight ratio between the nonionic surfactant and the peracetic acid is less than or equal to 0.2.

Abstract: Methods for rapid detoxification of patients addicted to opioid narcotics are provided. The methods include administering nalmefene to induce acute withdrawal, and administering dextromethorphan with nalmefene or other opioid antagonists to reduce the patient's subjective feelings of residual withdrawal symptoms following detoxification. In one method of rapid detoxification, unconsciousness is induced by anesthetizing the patient with desflurane.

Abstract: Disclosed herein are microemulsion insecticides that do not contain conventional actives. The microemulsion form permits insects to be killed by an oil/surfactant combination.

Abstract: Methods are provided to prepare a variety of tissues in a pathology-stable form keyed to the use of an aqueous solution of C.sub.2-6 dialdehyde and/or dialdehyde addition products, including the group consisting of glyoxal and/or glutaraldehyde in an amount sufficient to prevent autolysis and other degradative changes in various tissues. The said solution is capable of treating a tissue so as to maintain the tissue in a condition suitable for pathology and/or other experimental observation. The stabilizing solution is also useful to prepare parts or whole animals and plants in an anatomically preserved state for a prolonged period of time, and compositions useful in that method.

Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.

Abstract: Somatic mammary cells are defended from an action of glucocorticoid hormones by an insect pheromones of non-steroid nature, its derivative or a synthetic analog.

Abstract: This invention is directed towards stabilizing the biocidal activity of an alkyd composition containing a halopropargyl compound and a transition metal drier by use of a chelating agent.

Abstract: Alk-1-enyl glycerol derivatives and method of preparing same. The derivatives stimulate cell and tissue growth.

Abstract: Concentrated aqueous liquid disinfectant compositions which exhibit a blooming effect when diluted in a larger volume of water are provided. The concentrate compositions include non-phenolic constituents to provide a disinfecting effect, and are non pine-oil containing. Working strength dilutions of the concentrated aqueous liquid disinfectant compositions are effective against gram positive type pathogenic bacteria such as Staphylococcus aureus, as well as gram negative type pathogenic bacteria such as Salmonella choleraesuis.

Abstract: Methods for rapid detoxification of patients addicted to opioid narcotics are provided. The methods include administering nalmefene to induce acute withdrawal, and administering dextromethorphan with nalmefene or other opioid antagonists to reduce the patient's subjective feelings of residual withdrawal symptoms following detoxification. In one method of rapid detoxification, unconsciousness is induced by anesthetizing the patient with desflurane.

Abstract: Fluoroalkyl hydrocarbons as vehicles for pharmaceutical drugs are disclosed. These vehicles are particularly well-suited for delivering drugs which are insoluble in water or chemically unstable in aqueous media. Pharmaceutical solution compositions based on these vehicles have long shelf lives and provide improved drug bioavailability. In addition, the pharmaceutical compositions of the present invention are nonaqueous, and therefore do not require preservatives or tonicity agents. The invention is particularly useful in the field of ophthalmology.

Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.

Abstract: Novel derivatives of fatty acid analogs that have from one to three heteroatoms in the fatty acid moiety which can be oxygen, sulfur or nitrogen, are disclosed in which the carboxy-terminus has been modified to form various amides, esters, ketones, alcohols, alcohol esters and nitrites thereof.These compounds are useful as substrates for N-myristoyltransferase (NMT) and/or its acyl coenzyme, and as anti-viral and anti-fungal agents or pro-drugs of such agents. Illustrative of the disclosed compounds are fatty acid amino acid analogs of the structure ##STR1## in which x is the ethyl or t-butyl ester of an amino acid such as Gly, L-Ala, L-Ile, L-Phe, L-Trp, L-Thr or an amide such as NHCH.sub.2 C.sub.6 H.sub.5 or NH(CH.sub.2).sub.2 C.sub.6 H.sub.5.

Abstract: Use of D2-sevoflurane is disclosed as an inhalational anesthetic. Deuterated sevoflurane possess all of the desirable qualities of sevoflurane as an anesthetic and is metabolized more slowly thereby reducing potentially toxic inorganic fluoride release. More particularly, the compound fluorodideutero methyl 1,1,1,3,3,3-hexafluoropropyl ether is disclosed as well as a method for synthesis.

Abstract: An O/W type lipstick overcoat composition comprising (i) 2 to 80% by weight of a dimethyl polysiloxane, and/or a perfluoro polyether in an inner phase; and (ii) (a) water and (b) a silica powder and/or alumina powder in an outer phase or a W/O type lipstick overcoat composition (i) 40 to 70% by weight of a dimethyl polysiloxane in an outer phase and (ii) (a) water and (b) a silica powder and/or alumina powder in an inner phase.

Abstract: An industrial preservative antifungal composition containing and underwater antifouling composition comprising 4,5-dichloro-2-n-octyl-4-isothiazoline-3-one and/or 2-n-octyl-4-isothiazoline-3-one or salts thereof and 5-?2-(2-butoxyethoxy)ethoxymethyl!-6-propyl-1,3-benzodioxole and/or octachlorodipropyl ether as supplementary agent(s).

Abstract: An analgesic anaesthetic composition comprising up to 50% v.backslash.v nitrous oxide, the balance being oxygen and another respirable gas; characterized by the addition of an analgesically effective amount of an ether-based analgesic anaesthetic disposed in a single container above its pseudo-critical temperature at a pressure of up to 2000 psi, thereby to form and maintain a homogenous analgesic composition.

Abstract: A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung or hyperinflated lung syndrome, and instilling a perfluorochemical liquid into the trachea for administration in the alveolar sacs of a lung of the animal. The perfluorochemical is permeable to the ambient gas and resides substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O.sub.2 /CO.sub.2 blood gas exchange. In another aspect of the invention, the method further includes the step of alleviating the lung disorder without inducing hyperinflated lung syndrome.

Abstract: Various .beta.,.gamma.-dihydropolyprenyl alcohol derivatives having the formula: ##STR1## wherein n is an integer of 5 to 7 and R is hydrogen, a lower alkyl group or an aliphatic or aromatic acyl group are effective at pritigating stress in animals.

Abstract: Farnesyl derivatives, particularly farnesyl acetate, are used to reduce the level of protein farnesylation in a mammalian host. The activity of proteins which require farnesylation for function is thereby reduced. The compounds may be administered to patients to reduce the overall level of ras protein activity, either alone or in conjunction with other drugs which act as competitive inhibitors of farnesyl protein transferase.

Abstract: Farnesyl derivatives, particularly farnesyl acetate, are used to lower the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity in cells, thereby reducing cholesterol biosynthesis. The compounds may be administered to hypercholesterolemia patients to reduce the overall level of serum cholesterol, either alone or in conjunction with other drugs conventionally used for the treatment of hypercholesterolemia.

Abstract: The use of particular opioids to induce and maintain anesthesia and conscious sedation is disclosed. The opioids used in the method of the present invention relate to the anesthetic action of the N-phenyl-N-(4-piperidinyl)amides as disclosed in U.S. Pat. No. 5,019,583 to Feldman, et al.

Abstract: Use of D2-sevoflurane is disclosed as an inhalational anesthetic. Deuterated sevoflurane possess all of the desirable qualities of sevoflurane as an anesthetic and is metabolized more slowly thereby reducing potentially toxic inorganic fluoride release. More particularly, the compound fluorodideutero methyl 1,1,1,3,3,3-hexafluoropropyl ether is disclosed as well as a method for synthesis.

Abstract: Compositions for topical treatment of lesions of human or animal skin which comprise dimethyl ether to freeze the tissue and an acid capable of dissolving the intercellular matrix of the lesion. The dimethyl ether and acid are present in the composition in amounts effective to remove the lesion in a single treatment by a combination of cryogenic and keratolytic action. Methods are provided for the topical treatment of lesions of the skin of human or animal subjects comprising direct spray or intermediate swab application of the present compositions to the lesions.

Abstract: A .beta.,.gamma.-dihydropolyprenyl alcohol derivative having the formula: ##STR1## wherein n is an integer of 5 to 7 and R is hydrogen, a lower alkyl group or an aliphatic or aromatic acyl group, is new and usrful as a prophylactic therapeutic agent for human and animal immuno-deficiency deseases and phylactic agent against human and animal infectious deseases. Another disclosed polyprenyl compound is also useful as the same agent.

Abstract: The invention provides a concentrate for dilution with water in the preparation of an agricultural composition for application to crops, soil or animals and comprising an agricultural chemical whose agricultural activty varies with the pH of the water; and the invention provides a method of preparing such agricultural composition by mixing the concentrate with water and effecting such pH modification to the composition as is necessary to obtain a pH in the composition at which the agricultural activity of the chemical is acceptable. The concentrate comprises an active ingredient and a pH indicator for colouring the water, and the proportions of pH indicator and active ingredient are selected so that when the concentrate is diluted with water to provide an effective concentration of active ingredient in the water, the pH indicator indicates visually whether or not the pH of the water is suitable for acceptable agricultural activity of the chemical.

Abstract: A diluent for perfluorocarbons used for retinal unfolding (unfolding PFCL), consisting of a perfluorocarbon (diluent PFCL), which has a low viscosity and is volatile at room temperature, with a boiling point between body temperature (about 38.degree. C.) and 100.degree. C., for removing residual quantities of unfolding PFCL from the eye after performance of a retinal unfolding treatment. A method of treatment consisting of introducing into an eye the above diluent for the above purpose.

Abstract: A substantially anhydrous composition suitable for topical application which contain 10-80% by weight of an anhydrous base which is liquid or semi-solid at room temperature; and 5-50% by weight of polyolefin microspherical particles having an average diameter of less than 25 microns, the amount of microspherical particles constituting at least 30% by weight of the anhydrous base.

Abstract: A method for treating a patient to effect the remission of disorders associated with allergies, particularly asthma, by administering to the patient in need of such treatment a glycerol ether in a therapeutically effective amount sufficient to cause remission of such discomfort.

Abstract: A method of removing virus from white blood cells without causing concurrent damage to any red blood cells is provided by treating the white blood cells with an effective amount of a special detergent which selectively lyses the white blood cells without causing substantial lysis of any red blood cells in admixture therewith.

Abstract: The invention involves a granulating composition composed of an aqueous solution of magnesium sulfate heptahydrate and sodium hexametaphosphate. This composition can be used to prepare granules of ingredients for inclusion in any formulation for which rapid disintegration or dispersion are important factors. It is useful for tablets containing ingredients which are difficult to compress and is particularly useful for formulating swallowable tablets of a single non-soluble ingredient such as calcium carbonate. Disintegration times are markedly decreased.

Abstract: There is provided a novel perfluorochemical represented by the formula, ##STR1## wherein R.sub.F is a perfluoroalkyl group, a perfluoro alkoxyalkyl group or a perfluoroalkyloxy group, X and X' are same as or different from each other and are a fluorine atom or a perfluoroalkyl group, and Y is a perfluoroalkyloxy group or a perfluoro dialkylamino group, the total number of the carbon atoms contained being an integer of 8 to 11 inclusive. The perfluorochemical is prepared by perfluorinating the corresponding partially fluorinated compound which may have unsaturated hydrocarbon moiety, only with molecular fluorine in a stoichiometric excess amount in an inert solvent.The perfluorochemical is used for preparing a stable emulsion as blood substitutes or perfusion media.

Abstract: A single-phase, either isotropic or anisotropic formulation is disclosed, which contains perfluorinated oil and one or more surfactant(s), is useful as an excipient for cosmetic and dermatologic formulations and is characterized in that at least one surfactant is selected from those having the following general formula: ##STR1## wherein: R.sub.F is an F--(CF.sub.2 --CF.sub.2).sub.i -- group;X is a group selected from: ##STR2## --(CH.sub.2 --O).sub.K --; and --(CH.sub.2 --S).sub.K --; wherein R.sup.I is a (C.sub.1 -C.sub.4)-alkyl;Y is a group selected from: NH.sub.2 (R.sup.II).sub.2 and N(R.sup.II).sub.4 ; wherein R.sup.II is a hydrogen atom, or a group selected from --CH.sub.2 --CH.sub.2 --OH and (C.sub.1 -C.sub.4)-alkyl;i is an integer comprised within the range of from 3 to 8;i is zero or 1;K is 2.l;l is an integer comprised within the range of from 1 to 10;m is 1 or 2.Such composition is spontaneously formed when the components are simply placed into contact with one another.

Abstract: A composition is described for the dissolution of cholesterol gallstones, which composition is a mixture of monooctanoin and diethyl ether and has a viscosity of not more than 7 cp and can be maintained in the body at a temperature below its boiling point. The volumetric ratio of monooctanoin:diethyl ether will usually be in the range of about 10:90 to about 70:30. The composition can be infused by a variety of techniques including high flow low pressure pumps.

Abstract: The present invention is directed to an anestesia inducing composition comprising a mixture of oxygen gas and an anesthesia inducing effective amount of a compound 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane having the formula ##STR1## The present invention is also directed to methods of inducing and/or maintaining anesthesia by administering the composition in sufficient amounts to warm blooded animals.

Abstract: Solutions of microbiocides in cosolvents having alkanol moieties and concentrate compositions of carriers, microbiocides and cosolvents having alkanol moieties are stabilized against UV-catalyzed oxidation by the addition of phenolic antioxidants. The solutions or concentrate compositions are added to polymeric resins and formed, e.g., by fusion, into polymer compositions exhibiting microbiocidal properties.

Abstract: Method for dissolving cholesterol calculus in vitro or in vivo comprising contacting the cholesterol calculus with methyl tertiary-butyl ether.

Abstract: A controlled slow release pest control composition comprising an encapsulated pesticide, carbon and plaster.

Abstract: Compositions are provided comprising a polymer processing aid, and from about 5% to about 20% by weight, based on the total weight of the composition, of a microbiocidal compound, said microbiocidal compound being present as the solute in an aryl alkanol solvent, and the aryl alkanol solvent being present in an amount such that the weight ratio of the aryl alkanol solvent to microbiocidal compound is from about 3/1 to about 5/1.

Abstract: Provided are microbiocidal solutions comprising an aryl alkanol solvent and a microbiocidal compound dissolved therein. The solutions may be used to impart microbiocidal properties to polymer compositions.

Abstract: A topical preparation for treating an epidermal area of a human being infected with Herpes simplex virus comprising a stable solution or emulsion of from approximately 30% by volume to approximately 50% by volume of anhydrous ethyl ether in a pharmaceutically acceptable carrier oil of vegetable origin of about C.sub.6 to C.sub.20, having most of the free fatty acids thereof removed, said emulsion having a boiling point of at least 100.degree. F. The oils are preferably lauric acid oils. The method for treating in vivo an epidermal area of a human being infected with Herpes simplex virus includes the step of applying to the infected area in an amount sufficient to cover the infected area the topical preparation. In another embodiment of the method heat subsequently is applied to the area to which the topical preparation is applied.

Abstract: A topical preparation for treating an epidermal area of a human being infected with Herpes simplex virus comprising a stable emulsion having from approximately 30% by volume to approximately 50% by volume of anhydrous ethyl ether in a pharmaceutically acceptable coconut oil carrier having most of the free fatty acids thereof removed, said emulsion having a boiling point of at least 100.degree. F. The method for treating in vivo an epidermal area of a human being infected with Herpes simplex virus includes the step of applying to the infected area in an amount sufficient to cover the infected area the topical preparation. In another embodiment of the method heat subsequently is applied to the area to which the topical preparation is applied. In one preferred mode of this embodiment of the method the heat is applied approximately three minutes after the topical preparation is applied and the application of heat maintained for a period of between about 3 and 15 minutes.

Abstract: This invention relates to novel compounds having pharmaceutical activity and having the general structure ##STR1## wherein the Z, R.sub.1, R.sub.2, R.sub.3, R.sub.4, n and m are defined within.

Abstract: 3-(3-Hydroxybutoxy)-1-butanol having formula II and its stereoisomers and optical isomers, at the pure state, are described ##STR1## Processes for the purification of II and for the preparation of a pure diastereoisomer of II are described. Pharmaceutical compositions containing as the active ingredient compound II alone or combined with the isomeric ethers 4-(3-hydroxybutoxy)-2-butanol I and 3-(3-hydroxy-1-methylpropoxy)-1-butanol III.

Abstract: Disclosed is an improved method for controlling mosquitos wherein a body of water containing immature forms of mosquitos has its surface coated with a thin film of a control agent which is a non-ionic, organic material with a density less than that of water. The improvement in such method comprises coating the surface with an approximately monomolecular film of a .beta.-branched alcohol of the following structure: ##STR1## where R.sub.1 and R.sub.2 is C.sub.9 -C.sub.28 ; andR.sub.1 and R.sub.2 is at least C.sub.3, orR.sub.2 is CH.sub.3 and R.sub.1 has at least two branch sites.

Abstract: According to the invention, the parenteral administration of water-insoluble pharmacologically active agents is enhanced wherein the agents are administered in the lipoid phase of a carrier emulsion comprising a microemulsion of a finely dispersed lipoid in an aqueous phase. The lipoid preferably has a mean particle size below 1 micron. This makes it possible to administer water-insoluble agents in high concentrations, and thus a lower dose, whereby a rapid onset of the pharmacological effect is accompanied by a markedly reduced incidence of injury to body tissues.